MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING DISCRETE EVENT SIMULATION (DES)

Author(s)

Marton J1, Getsios D2, Revankar N2, Willke RJ1, Li Q2, Ishak KJ3, Caro JJ2, Zou KH1, Xenakis J41Pfizer, Inc., New York, NY, USA, 2United BioSource Corporation, Lexington, MA, USA, 3United BioSource Corporation, Dorval, QC, Canada, 4University of North Car

OBJECTIVES: Smoking cessation models have typically evaluated the impact of a single quit attempt on long term outcomes in smokers but smoking cessation is characterized by multiple quit attempts.  A DES was developed to simulate lifetime smoking patterns and the impact on smoking-related complications and costs.  This study evaluates the effect on predictions when modeling single versus multiple quit attempts. METHODS: Using data from trials, surveys, and the literature, the DES simulates individuals’ lifetime smoking behaviors and their impact on outcomes.  The simulation assigns and reassigns the initial outcomes of each quit attempt, time between quit attempts, relapses, and interventions used in each attempt (varenicline, bupropion, nicotine replacement, behavioral modification, unassisted).  Comorbidities include myocardial infarction, stroke, COPD, and lung cancer.  Market survey data are used to assign the initial intervention for quit attempts. Only direct costs (2010 $US) are considered.  All outcomes are discounted at 3%/year. RESULTS: When analyses are restricted to a single quit attempt, mean life expectancy in the population is 15.8 years, and QALYs 13.2; the lifetime costs of treatment and smoking related comorbidities average $55,925. Allowing for multiple quit attempts (average 7.6 attempts/smoker) increases the average time individuals spend abstinent by 8.8 years.  Consequently, predicted life expectancy increases by 1.1 years; QALYs by 0.9. Despite increased smoking intervention costs, total lifetime costs fall by $3300/smoker.   Analyses comparing initial varenicline treatment to mixed initial treatments and allowing multiple versus single quit attempts reduces varenicline-related predicted health gains and cost offsets, although both groups have better outcomes with multiple quit attempts. The reduction is apparent because individuals initially on less effective treatments are able to quit smoking in subsequent attempts. Nevertheless, varenicline is dominant or highly cost-effective in both scenarios.  CONCLUSIONS: Allowing multiple rather than single quit attempts in simulating outcomes for smokers provides better information for decision making.

Conference/Value in Health Info

2011-05, ISPOR 2011, Baltimore, MD, USA

Value in Health, Vol. 14, No. 3 (May 2011)

Code

PRS45

Topic

Methodological & Statistical Research

Topic Subcategory

Modeling and simulation

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×